495 related articles for article (PubMed ID: 19451330)
1. Do users of the intrauterine system (Mirena) have different genital symptoms and vaginal flora than users of the intrauterine contraceptive device?
Neale R; Knight I; Keane F
Int J STD AIDS; 2009 Jun; 20(6):423-4. PubMed ID: 19451330
[TBL] [Abstract][Full Text] [Related]
2. Effects of intrauterine device and oral contraceptive on vaginal flora and epithelium.
Ocak S; Cetin M; Hakverdi S; Dolapcioglu K; Gungoren A; Hakverdi AU
Saudi Med J; 2007 May; 28(5):727-31. PubMed ID: 17457440
[TBL] [Abstract][Full Text] [Related]
3. Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device.
Donders GG; Berger J; Heuninckx H; Bellen G; Cornelis A
Contraception; 2011 Apr; 83(4):352-6. PubMed ID: 21397094
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
[TBL] [Abstract][Full Text] [Related]
5. Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-releasing intrauterine system (LNG-IUS).
Lessard T; Simões JA; Discacciati MG; Hidalgo M; Bahamondes L
Contraception; 2008 Jan; 77(1):30-3. PubMed ID: 18082663
[TBL] [Abstract][Full Text] [Related]
6. Intrauterine devices: an effective alternative to oral hormonal contraception.
Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
[TBL] [Abstract][Full Text] [Related]
7. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
Rose S; Chaudhari A; Peterson CM
Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
[TBL] [Abstract][Full Text] [Related]
8. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
9. Impact of contraceptive initiation on vaginal microbiota.
Achilles SL; Austin MN; Meyn LA; Mhlanga F; Chirenje ZM; Hillier SL
Am J Obstet Gynecol; 2018 Jun; 218(6):622.e1-622.e10. PubMed ID: 29505773
[TBL] [Abstract][Full Text] [Related]
10. The impact of copper-containing and levonorgestrel-releasing intrauterine contraceptives on cervicovaginal cytology and microbiological flora: a prospective study.
Erol O; Simavlı S; Derbent AU; Ayrım A; Kafalı H
Eur J Contracept Reprod Health Care; 2014 Jun; 19(3):187-93. PubMed ID: 24738915
[TBL] [Abstract][Full Text] [Related]
11. Vaginal douching and development of bacterial vaginosis among women with normal and abnormal vaginal microflora.
Hutchinson KB; Kip KE; Ness RB;
Sex Transm Dis; 2007 Sep; 34(9):671-5. PubMed ID: 17413534
[TBL] [Abstract][Full Text] [Related]
12. Intrauterine devices and intrauterine systems.
ESHRE Capri Workshop Group
Hum Reprod Update; 2008; 14(3):197-208. PubMed ID: 18400840
[TBL] [Abstract][Full Text] [Related]
13. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism--a randomized comparative study.
Ng YW; Liang S; Singh K
Contraception; 2009 Jan; 79(1):24-8. PubMed ID: 19041437
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and Candida.
Donders GGG; Bellen G; Ruban K; Van Bulck B
J Med Microbiol; 2018 Mar; 67(3):308-313. PubMed ID: 29458551
[TBL] [Abstract][Full Text] [Related]
15. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy.
Donders GG; Van Calsteren K; Bellen G; Reybrouck R; Van den Bosch T; Riphagen I; Van Lierde S
BJOG; 2009 Sep; 116(10):1315-24. PubMed ID: 19538417
[TBL] [Abstract][Full Text] [Related]
16. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand.
Harrison-Woolrych M; Zhou L; Coulter D
N Z Med J; 2003 Aug; 116(1179):U538. PubMed ID: 14513085
[TBL] [Abstract][Full Text] [Related]
17. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women.
Lyus R; Lohr P; Prager S;
Contraception; 2010 May; 81(5):367-71. PubMed ID: 20399942
[TBL] [Abstract][Full Text] [Related]
18. Bacterial vaginosis.
Priestley CJ; Kinghorn GR
Br J Clin Pract; 1996 Sep; 50(6):331-4. PubMed ID: 8983322
[TBL] [Abstract][Full Text] [Related]
19. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
20. Severe seborrhoeic dermatitis: side-effect of the Mirena intra-uterine system.
Karri K; Mowbray D; Adams S; Rendal JR
Eur J Contracept Reprod Health Care; 2006 Mar; 11(1):53-4. PubMed ID: 16546818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
